Clinical Trials for Women’s Cancers

Medical College of Wisconsin physicians who specialize in gynecologic cancers collaborate with researchers and academic medical centers around the country to advance the understanding and treatment of ovarian, cervical, uterine, vulvar and vaginal cancers. Their patients – and the entire region – are the direct beneficiaries of ongoing research.

The Gynecologic Cancer Program is an active member of the Gynecologic Oncology Group (GOG), an organization that coordinates multi-center clinical trials to advance the treatment of gynecologic cancers. The program is also involved with the Radiation Therapy Oncology Group (RTOG). Both are cooperative research groups funded by the National Cancer Institute.

Our physicians are also working to establish a Women’s Health Research Initiative and a tissue bank to advance the understanding of female cancers.

Ongoing studies provide access to the best research has to offer in advanced treatments and improved quality of life.

The following clinical trials are open to enrollment.

To obtain information regarding any gynecologic clinical trials that our department has open, please contact our research team at 1-855-771-9477 or Email Us.

Type of CancerProtocol ID & Study Title
CervicalAnti PD-L1 Atezolizumab)
Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer
Keywords: Cervical Cancer, Atezolizumab, Cisplatin, Chemoradiotherapy, Node Positive, Anti PD-L1
CervicalIovance-C-145-04
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Cervical Carcinoma
Keywords: Cervical cancer, recurrent , metastatic, LN-145, TILs
EndometrialEndoBARR
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma.
Keywords: Recurrent Endometrial Cancer, Endometrial Carcinoma, Endometrial, Atezolizumab, Bevacizumab, Rucaparib
EndometrialTesaro TSR-042 4010-01-001
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD1 Monoclonal Antibody in Patients with Advance Solid tumors
Keywords: Endometrial, Tesaro, TSR-042, Advanced, 4010-01-001, Phase 1, Anti-PD1 Monoclonal Antibody, Solid Tumors
OvarianCORT125134-552 (Corcept)
A Phase 2, Randomized, Open-label, 3-arm Study of Relacorilant in Combination with Nab-Paclitaxel for Patients with Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Fallopian Tube, Primary Peritoneal, Nab-Paclitaxel, Relacorilant, Corcept, CORT125134-552
OvarianNRG -GY021
The study is intended to determine whether olaparib plus tremelimumab has adequate safety in the study population and to compare the progression-free survival (PFS) duration of olaparib monotherapy versus olaparib plus tremelimumab in women with recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Keywords: Ovarian, Recurrent Ovarian Cancer, Platinum-Sensitive Ovarian Cancer, Olaparib, PARP inhibitor, Tremelimumab, CTLA4 immune checkpoint inhibitor, Immunotherapy, high-grade serous, high-grade endometrioid, BRCA1 or BRCA2 mutation
OvarianCelsion 201-17-201
One of the purposes of this study is to test the safety of GEN-1 when given in combination with the standard of care chemotherapy (carboplatin and paclitaxel every 3 weeks for a total of 3 administrations), then surgery to remove your cancerous tissue, followed by additional standard of care chemotherapy (carboplatin and paclitaxel every 3 weeks for a total of 3 administrations). GEN-1 is an experimental drug (not approved by the Food and Drug Administration; FDA) that stimulates your immune system and may help your body kill cancer cells. It is given into the abdominal cavity through a special catheter (tube) placed under the skin. This is called intraperitoneal therapy (IP).
Keywords: Ovarian, Gen-1, Primary, Neoadjuvant, Intraperitoneal
OvarianThe OVAL Study
A Randomized, Controlled, Double-Arm, Double Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Other Study Identifiers: VB-111-701, GOG-3018
Keywords: Recurrent Ovarian Cancer, Platinum Resistant Ovarian Cancer, Ovarian, Ovarian Carcinoma, Epithelial Ovarian Cancer, Paclitaxel, VB-111, GOG-3018
OvarianGOG-3020 / ENGOT-ov45/NCRI/ATHENA
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients.
Keywords: Ovarian, Parp, Rucaparib, ATHENA y, Nivolumab, Maintenance, primary therapy, Front-Line Platinum-Based
OvarianNRG-GY005
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Keywords: Randomized, Cediranib, Olaparib, Ovarian, Platinum Resistant
OvarianNRG-GY007
A Phase I/II STUDY OF Ruxolitinib With Front-Line Neoadjuvant And Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Keywords: Ruxolitinib, Neoadjuvant, Epithelial Ovarian
OvarianNRG-GY-016
A Phase 2 Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the Ovary
Keywords: Ovarian Cancer, Clear Cell, Recurrent, Persistent, Pembrolizumab and Epacadostat
OvarianIIT-Uyar Merck 3475-250
Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer
Keywords: Suboptimal Cytoreduced, Ovarian, Pembrolizumab, First Line, Epithelial, Nonrandomized
Ovarian and EndometrialSutro- STRO-002-GM1
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an anti-Folate Receptor alpha (FolRα) Antibody Drug Conjugate (ADC), in Patients with Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Keywords: Advance Epithelial Ovarian Cancer, Fallopian Tube, Primary Peritoneal and Endometrial Cancer, Folate Receptor Alpha
Recurrent Platinum Sensitive Ovarian CancerRoche Y040482
A phase IB study of cobimetinib administered in combination with niraparib, with or without atezolizumab, to patients with advanced platinum-sensitive ovarian cancer
Keywords: Ovarian, Platinum Sensitive, Recurrent, Cobimetinib, Niraparib, Atezolizumab, Parp Inhibitor, Immunotherapy, Phase 1